Akeso jumps as cancer drug helps patients live longer in China trial

Akeso

01/06/2026 06:30

** Shares of China-based antibody drugs developer Akeso Inc 9926.HK jump 12.3% to HK$132.6, their highest since May 13
** An experimental drug developed by Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' 688235.SS immunotherapy Tevimbra, and cut the risk of death by more than one-third in a study presented at a medical meeting on Sunday
** Patients who received ivonescimab and chemotherapy lived an average of 27.9 months, compared with 23.7 months for those who received Tevimbra and chemotherapy, according to a brief summary of the study results
** The results are being presented at the American Society of Clinical Oncology meeting in Chicago on Sunday
** Shares of BeOne Medicines' 688235.SS slip 3% to 236.68 yuan, on track for the biggest one-day pct drop since May 18
** YTD, Akeso stock up 4.7%, while Hang Seng Biotech Index .HSBIO down 6.6%  


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))